NCT06423911 Phase 3 Recruiting
Study of Olverembatinib (HQP1351) in Patients With CML-CP Study sponsor: Ascentage Pharma Group Inc.
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2027-06-30 Estimated
Enrollment · participants 333 Estimated
Source updated 2026-09-15 Last update listed in the registry record
Version history
Changes to this trial Last 12 months
Posted 2026-09-15 · 3 fields changed
Main study measure wording changed
Text changed; whether the study measures changed has not been verified. Saved text may be shortened.
Compare wording
− Before Measure: MMR rate Part A
Measure: MMR rate Part B
+ After Measure: 24-Week MMR Rate ( Part A)
Measure: 24-Week MMR Rate ( Part B)
Planned enrollment increased by 48 participants
− Before 285 participants (planned)
+ After 333 participants (planned)
Primary completion date changed
Check registry source
This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial